Clinical Trial: Retrospective Analysis of Rituximab-containing Immunochemotherapy for Burkitt's or Burkitt-like Lymphoma in Adults
Study Status: Completed
Recruit Status: Completed
Study Type: Observational
Official Title: Rituximab-Containing Immunochemotherapy for Burkitt's Lymphoma (BL) and High-Grade B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell
Brief Summary: This retrospective study is aimed at evaluating the safety and efficacy of rituximab-containing immunochemotherapy in adult patients with Burkitt's lymphoma (BL) or high-grade B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and BL.
Detailed Summary:
Inclusion criteria
- pathologically confirmed BL or BL-U by World Health Organization 2008 criteria
- age >20 yrs
- received rituximab+chemotherapy as first-line treatment
- with measurable or evaluable lesion
- with complete set of clinical and laboratory data for the analysis
Sponsor: Gachon University Gil Medical Center
Current Primary Outcome: Event-free survival [ Time Frame: one year ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
- complete response rate [ Time Frame: 1-year ]treatment response will be evaluated according to the Revised criteria for malignant lymphoma (Journal of Clinical Oncology 25:579-586)
- overall survival [ Time Frame: 1-year ]Overall survival is defined as the time from treatment initiation until death as a result of any cause
- Grade 4 hematologic toxicities [ Time Frame: one year ]toxicities will be graded according to Common Toxicity Criteria for Adverse Events (CTCAE) V.4.0. Hematologic toxicities planned to evaluated were; anemia (by hemoglobin), absolute neutrophil count, and platelet count
Original Secondary Outcome: Same as current
Information By: Gachon University Gil Medical Center
Dates:
Date Received: March 8, 2013
Date Started: February 2013
Date Completion:
Last Updated: February 22, 2017
Last Verified: February 2017